Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Make 6x the impact through Facebook matching gift

Make 6x the impact through Facebook matching gift! Exciting news! When you donate to OMF’s Facebook Fundraiser tomorrow, Tuesday, November 30, 2021, (International Giving Tuesday), your gift of any amount will be matched by 6x!  Tomorrow only, Facebook will match up

Read More »

$3 million pledge received for research!

$3 million pledged for new study at the Collaborative Research Center at Montréal! #TripleGivingTuesday Research News From the desk of Alain Moreau, PhDDirector of the Collaborative Research Center at the CHU Sainte-Justine/Université de Montréal There is just one week left for

Read More »

Grateful for you 💗

  We would like to take a moment to acknowledge just how thankful we are to have you as a part of our OMF family.  Your support fills us with gratitude, your resilience inspires us, and your investment makes our

Read More »

Our #TripleGivingTuesday goal is now $1 million! 🎉

New matching donors raise the #TripleGivingTuesday goal to $1 million! OMF is thrilled to announce that two new matching gift donors have stepped up with matching gifts totaling $200,000, raising our TRIPLE GIVING TUESDAY OMF goal to $1,000,000! If you have

Read More »

An update from Dr. Ron Davis

From the Desk of Ronald W. Davis, Ph.D.Chair, OMF Scientific Advisory BoardDirector, ME/CFS Stanford Collaborative Research An update from Dr. Ron Davis: Improving diagnostic tools for ME/CFS #TripleGivingTuesday Research Update As OMF comes closer to the end of its #TripleGivingTuesday campaign,

Read More »

We’re increasing our #TripleGivingTuesday goal!

We’re increasing our Triple Giving Tuesday goal! OMF is thrilled to announce two additional anonymous matching gift donors have stepped up with matching gifts totaling $200,000! This means that our new TRIPLE GIVING TUESDAY OMF goal is $800,000! If you have

Read More »

OMF funds new treatment-focused project

#TripleGivingTuesday Research Update: OMF Funds New Treatment-Focused Project From the desk of Ronald Tompkins, MD, ScDChief Medical Officer, Open Medicine Foundation About the Project As we reach the midway point of #TripleGivingTuesday, I’m thrilled to share with you the details

Read More »

OMF Awarded 2nd Score of 100 on Charity Navigator!

OMF Awarded Score of 100 on Charity Navigator! OMF is proud to share that we have received our second score of “100 Encompass Rating” in the Leadership & Adaptability category on Charity Navigator! Last year, we received a score of 100 for the Finance

Read More »
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.


In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.


The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.


About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.


Heather Ah San

Development and Communications Manager